Through its 2018 acquisition of SynCo Bio Partners B.V. in Amsterdam, the Netherlands, Wacker Chemie AG strengthened its pharmaceutical protein business and expanded its portfolio – an important step to keep pace with the rapidly growing biologics market. As a result, Wacker Biotech now has three sites: Jena, Halle and Amsterdam, with a total of about 330 employees. (Photo: Wacker Chemie AG)

Dr. Susanne Leonhartsberger has been the managing director of Wacker Biotech GmbH since 2017, and, in her capacity as the head of the Biopharmaceuticals business line, is responsible for WACKER’s biologics business. “What especially motivates me is that we’re providing innovative medications for sick people all over the world – and that’s how most of us feel,” the biologist observes. (Photo: Wacker Chemie AG)

Production at Wacker Biotech GmbH: the Munich-based WACKER Group entered the field of contract manufacturing for pharmaceutical proteins when it acquired Prothera GmbH and subsequently renamed it Wacker Biotech in 2005. (Photo: Wacker Chemie AG)

Specialists in the field of microbial production: Wacker Biotech GmbH is a full-service contract manufacturer of biologics with more than 20 years of experience with microbial systems. The company’s core competencies include the manufacture of active pharmaceutical ingredients, vaccines and live bacteria. (Photo: Wacker Chemie AG)